

## Cipla receives approval for Pfizer's Depo-Provera

28 January 2019 | News | By Kalyani Sharma

**It is a progestin indicated only for the prevention of pregnancy**



Global pharma company, Cipla has announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Medroxyprogesterone Injectable, 150mg/mL from the United States Food and Drug Administration (US FDA).

Cipla's Medroxyprogesterone Injectable, 150mg/mL is AB-rated generic therapeutic equivalent version of Pfizer's Depo-Provera. It is a progestin indicated only for the prevention of pregnancy.

According to IQVIA (IMS Health), Depo-Provera and its generic equivalents had US sales of approximately \$159M for the 12-month period ending November 2018.